搜尋
Imunon Inc
IMNN添加自選
1.780USD
-0.020-1.11%
收盤 06/30, 16:00（美東）報價延遲15分鐘
7.48M總市值
虧損本益比TTM
關鍵數據
1.790今開
1.905最高
93.78K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
2.74%換手率
1.800昨收
1.725最低
109.48K成交額
虧損本益比靜
0.86市淨率
0.00%股息率 TTM
-196.78%ROA
41.21752週最高
1.42量比
-18.62M淨利潤
3.42M總股本
-3.9958每股盈餘TTM
1.97Beta
-768.25%ROE
2.08052週最低
10.00%振幅
100.00%毛利率
7.48M總市值
-3.87回報/風險
4.21%風險率
TradingKey Imunon Inc股票評分
單位: USD 更新時間: 2026-06-30操作建議
Imunon Inc當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名156/387位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為17.00。中期看，股價處於下降通道。近一個月，市場表現非常差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Imunon Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
看好
Imunon Inc亮點
亮點風險
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
估值低估
公司最新PE估值-0.45，處於3年歷史低位
機構加倉
最新機構持股431.10K股，環比增加9.85%
分析師目標
基於
4
分析師
買入
評級
17.000
目標均價
+844.44%
漲幅空間
Imunon Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Imunon Inc簡介
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
公司代碼IMNN
公司Imunon Inc
CEOLindborg (Stacy R)
網址https://imunon.com/
相關品種
-2.50%
-1.79%
-1.22%
-0.57%
-0.73%
-0.56%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%熱門品種
52184.500
-11.800 (-0.02%)
30081.600
-143.000 (-0.47%)
7468.400
-14.000 (-0.19%)
15290.000
-305.000 (-1.96%)
70591.000
-265.000 (-0.37%)
6319.500
-7.500 (-0.12%)
68.378
-1.543 (-2.21%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
3980.090
-27.190 (-0.68%)
常見問題
Imunon Inc(IMNN)的當前股價是多少？
Imunon Inc(IMNN)的當前股價是 1.78。
Imunon Inc 的股票代碼是什麼？
Imunon Inc的股票代碼是IMNN。
Imunon Inc股票的52週最高點是多少？
Imunon Inc股票的52週最高點是41.22。
Imunon Inc股票的52週最低點是多少？
Imunon Inc股票的52週最低點是2.08。
Imunon Inc的市值是多少？
Imunon Inc的市值是6.09M。
現在Imunon Inc(IMNN)的股票是買入、持有還是賣出？
根據分析師評級，Imunon Inc(IMNN)的總體評級為買入，目標價格為17.00。
Imunon Inc(IMNN)股票的每股收益（EPS TTM）是多少
Imunon Inc(IMNN)股票的每股收益（EPS TTM）是-6.83。